Can Fulgent Sustain Sky-High Growth Post-Pandemic?

Thursday, March 11, 2021 | Kate Stalter
Can Fulgent Sustain Sky-High Growth Post-Pandemic? Diagnostic test maker Fulgent Genetics (NASDAQ; FLGT) closed Wednesday at $97.20, down 11.28%, or $12.36. It’s hovering near its 50-day moving average.

The company reported its fourth-quarter results on March 4 after the close.

Fulgent posted revenue of $295 million and earnings per share of $6.20. Top-and bottom-line results were both up astronomically from the year-ago quarter’s sales of $8.4 million and earnings of $0.04 per share.

Revenue growth has been in the double digits for the past eight quarters and accelerated in the past three.

The company’s 2021 guidance calls for 90% growth in revenue.

Why the whopping increases and optimistic guidance? Chalk it up to Fulgent’s Covid testing products.

After the earnings report, Fulgent stock vaulted 31% intraday, to $112, before settling down to end Friday’s session at $92.34, a gain of $6.81, or 7.96%.

In the subsequent sessions, the stock bounced around the vicinity of its 50-day line, not yet gaining upside traction.

Doubts About Post-Covid Business

After such a stellar earnings report, why isn’t Fulgent rocketing higher?

Analysts and investors are uncertain whether the company can maintain those growth levels as the Covid-19 pandemic winds down. While the guidance for this year indicates confidence in continued strength, it’s unclear how Fulgent will continue to grow in 2022 and beyond.

Analysts expect the company to earn $12.39 per share this year, a 36% increase over 2020.

However, Wall Street sees those earnings numbers returning to earth in 2022, to $4.83 per share. That would be a 61% year-over-year decline.

Nonetheless, Piper Sandler boosted its price target to $140 from $135, rating the stock as overweight.

In addition to Covid testing products, Fulgent’s businesses include Beacon Carrier Screening, which checks for risk of severe inherited conditions.

Other lines of business include Parkinson’s, Alzheimer’s and dementia panels; chromosome testing; and cardiovascular, cancer and epilepsy panels.

In the earnings call, CEO Ming Hsieh cited the company’s next-generation sequencing panels. These are used to screen for numerous conditions, including night blindness, as well as cardiovascular, immunodeficiency and skeletal issues.

High Expectations For NSG Testing

 “Despite various lockdowns across the country, volume from NGS tests grow from 59,000 in 2019 to 72,000 in 2020,” said Hsieh.

He added, “Looking ahead in 2021, we expect our NGS business will grow above 92% year over year to $70 million. And looking at our business overall, we expect revenue to almost double in 2021compared to the record revenue achieved in 2020. Armed with our technology platform, we expect to continue to see strong growth and operating margins due to our best-in-class cost structure.”

Chief financial officer Paul Kim added that the company expects growth in its at-home testing platform, Picture Genetics, which supports Covid and non-Covid testing.

“On the non-COVID front, we continue to add content and introduce more tests into multiple areas, including oncology and reproductive health,” Kim said.

Fulgent has a market capitalization of $2.8 billion, which puts it in mid-cap territory.

Caught In A Short Squeeze?

It has a beta of 1.39, meaning it’s more volatile than the broader market. On its chart, it’s easy to see how the severity of intraday price swings intensified lately.

Some of that volatility is likely due to short covering.  As of February 12, in the midst of the volatile trading, the short percent of Fulgent’s float was 20.78%. That’s lower than in January, but still high.

The stock continues to show volatile trade.

It’s currently consolidating 49% below its February 9 high of $189.89. This is not an ideal place for investors to initiate a new position, particularly given the uncertainty about the company’s post-Covid business.

It’s certainly possible that the stock will rally in the coming months on strength of its non-Covid testing panels. But it’s also possible that it will languish or turn lower as Covid business gradually dwindles. This is a stock best left on a watch list for now.

Can Fulgent Sustain Sky-High Growth Post-Pandemic?

Featured Article: Return on Investment (ROI)



7 Cryptocurrencies That Are Leading The Market Higher

An Influx Of Capital Is Driving Cryptocurrency Higher

There is an influx of money to the cryptocurrency market that is driving the entire complex higher. Not only is institutional interest peaking but recognition and use are on the rise as well. With Bitcoin setting new all-time highs 100% above the 2017 highs the number of new Bitcoin millionaires is on the rise too.

But Bitcoin is not the only cryptocurrency on the market today by far. The number of cryptocurrencies on the market has been growing steadily with more than 4,000 listed on Coinmarketcap alone. But that doesn’t mean they are all worth your time. Many if not most will not stand the test of time.

One way to judge the market’s interest in a cryptocurrency is its market performance gains. A cryptocurrency that is gaining in value is certainly one that you may want to own. The better method of judging the market’s interest in a cryptocurrency is the market cap. The cryptocurrency market is worth upwards of $1 trillion and growing, and most of that value is centered in the top seven. Together, the bottom 3,993 odd cryptocurrencies only account for 12% of the market and have yet to prove any lasting value.

View the "7 Cryptocurrencies That Are Leading The Market Higher".


Companies Mentioned in This Article

CompanyMarketRank™Current PricePrice ChangeDividend YieldP/E RatioConsensus RatingConsensus Price Target
Fulgent Genetics (FLGT)1.4$74.64+2.2%N/A36.95Hold$74.40
Compare These Stocks  Add These Stocks to My Watchlist 

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.